source
- Summit pulls $500M share sale a day after announcing itThe developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.BioPharma Dive · 1mo ago↗ source
- Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec saysDHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendr…Endpoints · 1mo ago↗ source
- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.